ProteoTech

Targeting Amyloid Diseases

- **ProteoTech, Inc.** is a drug research and development Company that utilizes Proteoglycan and Amyloid Technologies to discover and commercialize new therapeutics and diagnostics for human amyloid diseases.
- Over 12 years of innovative research and development has led the Company to develop and generate a unique library of small molecule and small peptide compounds. These proprietary compounds specifically target different amyloid proteins that accumulate in various amyloid disorders including the beta-amyloid and tau protein of Alzheimer's disease, the alpha-synuclein of Parkinson's disease, the islet amyloid polypeptide of type 2 diabetes, and the AA amyloid protein of systemic amyloidosis.

Therapeutic and Diagnostic Technologies

ProteoTech was founded in 1996 by Dr. Alan D. Snow, a former Research Associate Professor of Pathology at the University of Washington (UW) in order to accelerate new discoveries pertaining to proteoglycan and amyloid technologies with the goal of developing novel therapeutics and diagnostics for amyloid disorders. Amyloid diseases include Alzheimer's disease, Parkinson's disease, and type 2 diabetes—all of which are indications that are continuing to reach epidemic proportions world-wide. The Alzheimer's and Parkinson's disease field of drug development has yet to identify disease-modifying solutions to these serious global health issues. ProteoTech has been successful in discovering proprietary classes of compounds that inhibit and disrupt amyloid protein fibril formation, accumulation and persistence in a variety of amyloid diseases.

Parkinson's Disease Therapeutic—*Synuclere*™

During the last 4 years, ProteoTech has been funded by the Michael J. Fox Foundation for Parkinson's Disease Research with a prestigious LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) award to develop a novel small molecule compound for the treatment of alpha-synuclein aggregation and accumulation in Parkinson's disease. The Company has identified and developed a small molecule compound (known as Synuclere™) and related back-up analogs that remarkably reduce alpha-synuclein aggregates in brains of alpha-synuclein transgenic mice following peripheral administration. In addition, Synuclere™- treated animals demonstrate marked improvements in motor deficits observed in older alpha-synuclein transgenic mice. *Synuclere™* is in late stage pre-clinical development for the treatment of Parkinson's disease.

OVERVIEW

ProteoTech, Inc.
12040 115th Ave., NE
Kirkland, WA 98034
Office: (425) 823-0400
Fax: (425) 823-8508
www.proteotech.com

TYPE OF COMPANY

Pharmaceuticals: Therapeutics and Diagnostics for Amyloid Diseases

DATE FOUNDED

June 1996

LEGAL COUNSEL

Fenwick & West, LLP
Seattle, WA

Ryan, Swanson & Cleveland
Seattle, WA

INTELLECTUAL PROPERTY

95 Patents
60 Issued (US/International)
35 Pending (US/International)

BOARD OF DIRECTORS

Alan D. Snow, Ph.D., Chairman, President and CSO
Steve Runnels, CEO
Dennis McCurley, COO & CFO
William T. Frantz

SCIENTIFIC BOARD OF ADVISORS

William Langston, M.D.
Murray Raskind, M.D.
Jeffrey Kaye, M.D.
Eliezer Masliah, M.D.
Benjamin Wolozin, M.D., Ph.D.
Manfred Weigele, Ph.D.

ProteoTech

Parkinson's Disease Imaging Agents



In collaboration with a pioneer imaging Company, ProteoTech is using its small molecule compounds and technology to develop an imaging agent to detect alpha-synuclein aggregates and deposits in the brains of Parkinson's disease patients. This work was also funded by a prestigious imaging award from the Michael J. Fox Foundation for Parkinson's disease research. ProteoTech has identified small molecule lead compounds that are believed to serve as potential PET imaging agents to detect alpha-synuclein aggregates in Lewy bodies (the pathological brain hallmark of Parkinson's disease).

Alzheimer's Disease Therapeutics

Exebryl-1®

One of ProteoTech's primary compound's for the treatment of Alzheimer's disease is Exebryl-1®, a proprietary small molecule that possesses potent beta-amyloid protein inhibitory activity for the treatment of Alzheimer's, at all stages of the disease. For Alzheimer's disease animal model testing, the Company's research studies used genetically engineered transgenic mice that mimic many of the neuropathological hallmarks of Alzheimer's disease. Exebryl-1® markedly inhibits the formation of brain amyloid plaques, and caused a marked clearance/removal of pre-existing brain beta-amyloid protein deposits. In addition, studies utilizing transgenic mice models to study Alzheimer's disease demonstrate a marked improvement in spatial learning and memory following Exebryl-1® treatment. Human phase 1A clinical trials for Exebryl-1® are in the process of being completed.

PeptiClere™

The Company has also identified and developed a small peptide (known as PeptiClere™) that markedly reduces brain amyloid load in Alzheimer's transgenic mice and causes marked improvements in spatial acquisition and memory following peripheral administration. PeptiClere™ is being developed by ProteoTech as a potential treatment of mild-to-moderate

Other Therapeutics in Development Pipeline

Type 2 Diabetes Therapeutics

For type 2 diabetes amyloid, ProteoTech has identified novel small molecules (representing new chemical entities) that markedly disrupt islet amyloid polypeptide (IAPP) fibrils that accumulate in the islets of Langerhans (in pancreas) in 90% of patients with type 2 diabetes. Lead compounds are to being developed for testing in transgenic animal models of islet amyloid accumulation in pancreas. It is believed that IAPP amyloid accumulation in pancreas leads to beta-cell (i.e. insulin producing cells) death and is an important neglected target for the treatment of diabetes.

Systemic AA Amyloidosis Therapeutics

Systebryl™

For systemic amyloidosis, the company has identified a small molecule compound (known as Systebryl™) (and related analogs representing new chemical entities) that following oral treatment markedly prevents and reduces AA amyloid deposition (in systemic organs including, liver, kidney and spleen) in a relevant animal model of systemic AA amyloidosis. This program is funded under Phase I and Phase II SBIR (Small Business Innovative Research awards) from the National Institutes of Health (National Institutes of Arthritis and Musculoskeletal and Skin Diseases). Systebryl™ and related analogs are in late-preclinical development for the treatment of systemic amyloidosis (orphan drug status).

SYNUCLERE™ PROGRAM

Synuclere™ disaggregates and causes removal of toxic alpha-synuclein amyloid—the key disease-modifying target for Parkinson's disease. Potentially the first in class and first in man compound developed for the treatment of Parkinson's disease.

EXEBRYL-1® PROGRAM

Studies have shown that Exebryl-1® may be the first Alzheimer's treatment in development that attacks both disease targets—beta-amyloid and tau protein.

PEPTICLERE™ PROGRAM

Small peptide in development showing promise as a treatment for Alzheimer's disease.

SYSTEBRYL™ PROGRAM

Small molecule in development for orphan drug indication, Systemic AA Amyloidosis, that has been shown to be safe for human use in preliminary human safety clinical trials.

TYPE 2 DIABETES PROGRAM

ProteoTech has identified small molecule candidates that markedly disrupt islet amyloid polypeptide aggregates, key to treatment of the disease.

Management Team


Alan Snow

Alan D. Snow, Ph.D. (President & CSO) is the Founder and Chairman of the Board. He served as a Research Associate Professor of Pathology at the University of Washington, and is a world-recognized authority on the role of proteoglycans in Alzheimer's and amyloid diseases, with over 20 years of experience in this area of research. At the University of Washington, Dr. Snow was the first to identify and demonstrate specific proteoglycans in amyloid deposits in Alzheimer's disease. Dr. Snow has co-authored several publications with Nobel laureate, Dr. Stanley Prusiner and was the first to identify specific proteoglycans in the brain amyloid deposits in a variety of prion diseases. He is the author of more than 50 scientific publications, has presented his research on amyloid disease and proteoglycans at over 120 scientific meetings, and is an inventor of 123 issued patents. Dr. Snow holds a B.S. in Chemistry/Biology from Bowling Green State University in Ohio, a M.S. in Anatomy from University of Western Ontario (London, Ontario, Canada) and a Ph.D. in Pathology from Queen's University (Kingston, Ontario, Canada).


Steve Runnels

Mr. Steve Runnels, MBA (CEO) has more than 26 years of international management experience in the healthcare industry. He has held the position of President and CEO of several start-up biopharmaceutical companies, executive vice president and Board member of publicly traded NeoTherapeutics, Inc. (NEOT: NASDAQ) and Vice President of Marketing and Business Development at Sigma-Aldrich, a Fortune 500 company. He has led drug discovery and *in vitro* diagnostic product development activities in the therapeutic areas of Central Nervous System, Oncology, Clinical Cytogenetics, Assisted Reproductive Technologies, Immunohematology and Diseases of Bone and Cartilage. He is a Senior Industry Advisor for the National Institutes of Health - Capitalization Assistance Program. Mr. Runnels holds a B.S. in Cell Biology and certification from the American Society of Clinical Pathology as a specialist in Immunohematology and is a Ph.D. candidate in Management.


Dennis McCurley

Dennis L. McCurley, M.B.A., (COO & CFO) is responsible for the daily operations at ProteoTech. He has held various senior management positions over the past 30 years including VP-Franchising, VP-Regional Manager with First Interstate Bancorp and CEO of Capital Access One. He earned his M.B.A. from the University of Southern California and an advanced degree from the University of Washington-Pacific Coast Banking School. Dennis is very involved in the community having served on several nonprofit boards. He is a guest lecturer at the University of Washington in Organizational Behavior and Business Ethics. He was also a founding member of several start-up companies before joining ProteoTech in 1997.

Rebecca Eagen, Ph.D., (Director of Intellectual Property) is responsible for managing the extensive and growing IP portfolio of the Company. Dr. Eagen is a Registered Patent Agent in the US and Canada and has specialized in pharmaceutical and biotechnology patents. She holds a Ph.D. in Molecular Biology and Biochemistry from the University of British Columbia, Vancouver, BC.

12040 115th Avenue NE
Kirkland, WA 98034
Phone 425.823.0400
Fax 425.823.8508

For more information on ProteoTech's technologies and drug discovery programs, please visit our website at: www.proteotech.com